EUVIMEDEUVIMED entdecken
Open Access

Metformin Use and Development of Esophageal Squamous Cell Carcinoma

Shao-Hua Xie, Giola Santoni, Helgi Birgisson, My von Euler-Chelpin, Joonas H Kauppila, Eivind Ness-Jensen, Jesper Lagergren

JAMA Network Open · 16.03.2026 · 9 (3) · e262027

DOI: 10.1001/jamanetworkopen.2026.2027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 16.03.2026. Verfasst von Shao-Hua Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, and Karolinska University Hospital, Stockholm, S…. Hauptthemen laut MEDLINE: Metformin, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis, stressing the need for preventive measures. A decreased risk of ESCC among metformin users has been suggested, but evidence is limited.

Objective

To assess whether metformin use, given its potential anticancer properties, is associated with risk of ESCC. Design, Setting, and Participants This population-based case-control study set between 1994 and 2023 looked at data from all 5 Nordic countries (ie, Denmark, Finland, Iceland, Norway, and Sweden). Participants were patients newly diagnosed with ESCC during the study period, and each was compared with 10 times as many control participants randomly selected from the general population (matched by age, sex, calendar year, and country). Exposures Use of metformin vs nonuse. Main Outcomes and Measures Conditional logistic regression provided odds ratios (OR) with 95% CIs for the association between metformin use and the development of ESCC. In addition to the matching, the ORs were adjusted for tobacco smoking, alcohol overconsumption, use of nonsteroidal anti-inflammatory drugs or aspirin, and use of statins. A dose-response analysis was conducted among participants with at least 5 years of observation time, based on the defined daily dose during the 5-year period.

Results

This study included 13 050 case patients with ESCC (8030 men [61.5%] and 5020 women [38.5%], diagnosed at a median age of 70 years [IQR, 62-77 years]), and 130 500 age- and sex-matched control participants. Metformin use was associated with a 36% lower odds of ESCC compared with nonuse (OR, 0.64; 95% CI, 0.59-0.69). The odds were especially lower in participants with a higher dosage of metformin (>1278 defined daily dose in 5 years: OR, 0.52; 95% CI, 0.44-0.61). Conclusions and Relevance In this case-control study, metformin use was associated with substantially lower odds of ESCC. This finding should prompt investigations of metformin as a preventive option in high-risk individuals and as a potential future therapeutic agent for ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsHypoglycemic AgentsHumansFemaleCase-Control StudiesMaleMiddle AgedAgedScandinavian and Nordic CountriesRisk Factors

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
  • Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Surgery Research Unit, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • HUNT Research Centre, NTNU, Levanger, Norway.
  • Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.

Zitieren

APA

Xie, S. H., Santoni, G., Birgisson, H., von Euler-Chelpin, M., Kauppila, J. H., Ness-Jensen, E., & Lagergren, J. (2026). Metformin Use and Development of Esophageal Squamous Cell Carcinoma. JAMA Network Open, 9(3), e262027. https://doi.org/10.1001/jamanetworkopen.2026.2027

Vancouver

Xie SH, Santoni G, Birgisson H, von Euler-Chelpin M, Kauppila JH, Ness-Jensen E, et al. Metformin Use and Development of Esophageal Squamous Cell Carcinoma. JAMA Network Open. 2026;9(3):e262027. doi:10.1001/jamanetworkopen.2026.2027

BibTeX
@article{Xie2026,
  author = {Xie, Shao-Hua and Santoni, Giola and Birgisson, Helgi and von Euler-Chelpin, My and Kauppila, Joonas H and Ness-Jensen, Eivind and Lagergren, Jesper},
  title = {Metformin Use and Development of Esophageal Squamous Cell Carcinoma},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {e262027},
  doi = {10.1001/jamanetworkopen.2026.2027}
}
Kostenlos starten →